{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:25:05Z","timestamp":1787138705246,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00638-6","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:36:37Z","timestamp":1787135797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plozasiran: a small interfering RNA therapy for hypertriglyceridemia and familial chylomicronemia syndrome"],"prefix":"10.1007","volume":"34","author":[{"given":"Jennifer","family":"Rodriguez-Montes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-1543","authenticated-orcid":false,"given":"Genevieve","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Benny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"3","key":"638_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1210\/clinem\/dgaf701","volume":"111","author":"RA Hegele","year":"2026","unstructured":"Hegele RA. Approach to the adult patient with chylomicronemia. J Clin Endocrinol Metab. 2026;111(3):845\u201359.","journal-title":"J Clin Endocrinol Metab"},{"key":"638_CR2","doi-asserted-by":"publisher","first-page":"119114","DOI":"10.1016\/j.atherosclerosis.2025.119114","volume":"403","author":"EA Brinton","year":"2025","unstructured":"Brinton EA, Eckel RH, Gaudet D, et al. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025;403:119114.","journal-title":"Atherosclerosis"},{"key":"638_CR3","unstructured":"Regmi M, Rehman A. Familial Hyperchylomicronemia Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Updated August 8, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551655\/.\u00a0Accessed\u00a019\u00a0Jan\u00a0 2026."},{"key":"638_CR4","unstructured":"Hannah-Shmouni F, Gonzales K, Genere N, editors. Familial chylomicronemia syndrome. Endocrine Society. January 24, 2022 https:\/\/www.endocrine.org\/patient-engagement\/endocrine-library\/familial-chylomicronemia-syndrome. Accessed\u00a0 2\u00a0Dec 2025."},{"issue":"2","key":"638_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/diseases14020047","volume":"14","author":"F Fogacci","year":"2026","unstructured":"Fogacci F, Cicero AFG. Hypertriglyceridaemia-associated acute pancreatitis: Risk stratification, drivers, and prevention of recurrence. Diseases. 2026;14(2):47.","journal-title":"Diseases"},{"issue":"11","key":"638_CR6","first-page":"e96715","volume":"17","author":"J Joshy","year":"2025","unstructured":"Joshy J, Javed A, Kumar Singh M, et al. A next-generation antisense therapy for hypertriglyceridemia and familial chylomicronemia syndrome. Cureus. 2025;17(11):e96715.","journal-title":"Cureus"},{"key":"638_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","volume":"275","author":"P Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an FCS score. Atherosclerosis. 2018;275:265\u201372.","journal-title":"Atherosclerosis"},{"key":"638_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.dib.2018.10.125","volume":"21","author":"P Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, et al. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data Brief. 2018;21:1334\u20136.","journal-title":"Data Brief"},{"issue":"4","key":"638_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/jcm11040982","volume":"11","author":"G Kolovou","year":"2022","unstructured":"Kolovou G, Kolovou V, Katsiki N. Volanesorsen: a new era in the treatment of severe hypertriglyceridemia. J Clin Med. 2022;11(4):982.","journal-title":"J Clin Med"},{"key":"638_CR10","unstructured":"Plozasiran, editor. (Redemplo) [Package insert]. Arrowhead Pharmaceuticals, Inc; November 2025."},{"key":"638_CR11","unstructured":"Plozasiran I. 2025. https:\/\/www.clinicalkey.com\/pharmacology\/monograph\/5635?sec=monindi . Accessed\u00a04 Dec 2025."},{"key":"638_CR12","unstructured":"Plozasiran I. 2025. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7655930.\u00a0Accessed\u00a0 4 Dec 2025."},{"key":"638_CR13","unstructured":"Study of ARO-APOC3 (Plozasiran) in adults with familial chylomicronemia syndrome (FCS) (PALISADE). Clinicaltrials.gov. Accessed December 12. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05089084"},{"issue":"2","key":"638_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N Engl J Med. 2025;392(2):127\u201337.","journal-title":"N Engl J Med"},{"key":"638_CR15","unstructured":"Study to evaluate ARO-APOC3 in adults with severe hypertriglyceridemia (SHASTA-2). Clinicaltrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT04720534.\u00a0Accessed\u00a019 Jan 2026."},{"issue":"7","key":"638_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: The SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330.","journal-title":"JAMA Cardiol"},{"key":"638_CR17","unstructured":"Study of plozasiran (ARO-APOC3) in adults with severe hypertriglyceridemia (SHASTA-3). Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06347003. Accessed\u00a020 Feb\u00a0 2026."},{"key":"638_CR18","unstructured":"Study of plozasiran in adults with severe hypertriglyceridemia (SHASTA-4). Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06347016.\u00a0Accessed\u00a020 Feb\u00a0 2026."},{"key":"638_CR19","unstructured":"Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3). Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06347133.\u00a0Accessed\u00a0 20\u00a0July 2026."},{"key":"638_CR20","unstructured":"Study of plozasiran in adults with severe hypertriglyceridemia at risk of acute pancreatitis (SHASTA-5). Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06880770?intr=Plozasiran&rank=3 . Accessed\u00a019\u00a0Jan 2026."},{"key":"638_CR21","unstructured":"Long-term safety and efficacy of plozasiran in adults with hypertriglyceridemia (SHASTA-10). Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06822790?intr=Plozasiran&rank=2 .\u00a0Accessed\u00a019\u00a0Jan\u00a0 2026."},{"key":"638_CR22","unstructured":"Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial. Updated 2026. https:\/\/arrowheadpharma.com\/news-press\/arrowhead-pharmaceuticals-to-advance-rnai-based-plozasiran-into-phase-3-capitan-cardiovascular-outcomes-trial\/.\u00a0Accessed\u00a020\u00a0Feb\u00a0 2026."},{"issue":"1","key":"638_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11883-025-01345-4","volume":"27","author":"S Tsimikas","year":"2025","unstructured":"Tsimikas S. Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease. Curr Atheroscler Rep. 2025;27(1):103.","journal-title":"Curr Atheroscler Rep"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00638-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00638-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00638-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:36:39Z","timestamp":1787135799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00638-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00638-6","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.This manuscript has not been submitted to another publication for simultaneous consideration. The submitted work is original and has not been published elsewhere in any form or language. No data, text, or theories by others are presented as if they were the authors\u2019 own. Proper acknowledgements to other works have been given as appropriate.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"61"}}